ProteoGenix :: Innovative clinical genomic and proteomic technologies to the focused mission of developing and marketing diagnostic tests during a woman’s pregnancy.

ProteoGenix At A Glance

Founded in 2002
ProteoGenix is first company to identify and map ~800 unique proteins in the proteome of pregnancy
Winner of the Best Clinical Study Award, 2007 Society for Maternal-Fetal Medicine
ProteoGenix’ vision is the application of unique biomarkers to develop and commercialize effective, non-invasive diagnostics that allow earlier and more accurate identification and treatment of significant complications of pregnancy such as intraamniotic infection, neonatal sepsis, preterm birth, preeclampsia and Down syndrome
Investors: New Leaf Venture Partners, Texas Pacific Group, Burrill & Company, Kaiser Permanente Ventures
Founded in 2002
ProteoGenix is first company to identify and map ~800 unique proteins in the proteome of pregnancy
Winner of the Best Clinical Study Award, 2007 Society for Maternal-Fetal Medicine
ProteoGenix’ vision is the application of unique biomarkers to develop and commercialize effective, non-invasive diagnostics that allow earlier and more accurate identification and treatment of significant complications of pregnancy such as intraamniotic infection, neonatal sepsis, preterm birth, preeclampsia and Down syndrome
Investors: New Leaf Venture Partners, Texas Pacific Group, Burrill & Company, Kaiser Permanente Ventures
Founded in 2002
ProteoGenix is first company to identify and map ~800 unique proteins in the proteome of pregnancy
Winner of the Best Clinical Study Award, 2007 Society for Maternal-Fetal Medicine
ProteoGenix’ vision is the application of unique biomarkers to develop and commercialize effective, non-invasive diagnostics that allow earlier and more accurate identification and treatment of significant complications of pregnancy such as intraamniotic infection, neonatal sepsis, preterm birth, preeclampsia and Down syndrome
Investors: New Leaf Venture Partners, Texas Pacific Group, Burrill & Company, Kaiser Permanente Ventures
Founded in 2002
ProteoGenix is first company to identify and map ~800 unique proteins in the proteome of pregnancy
Winner of the Best Clinical Study Award, 2007 Society for Maternal-Fetal Medicine
ProteoGenix’ vision is the application of unique biomarkers to develop and commercialize effective, non-invasive diagnostics that allow earlier and more accurate identification and treatment of significant complications of pregnancy such as intraamniotic infection, neonatal sepsis, preterm birth, preeclampsia and Down syndrome
Investors: New Leaf Venture Partners, Texas Pacific Group, Burrill & Company, Kaiser Permanente Ventures

about proteogenix

Today, two of the three most costly conditions treated in hospitals relate to pregnancy. These conditions are associated with significant medical consequences that can have life-long impact. ProteoGenix is the first and only company solely committed to developing non-invasive diagnostics that address unmet medical needs and improve pregnancy and neonatal management and outcomes.

By applying innovative genomic and proteomic technologies, ProteoGenix has quickly become a leader in developing powerful molecular diagnostic tools that have the potential to dramatically change the future of pregnancy and neonatal management.

more about